JoAnne L. Flynn, PhD

JoAnne L. Flynn, PhD


5058 Biomedical Science Tower 3
3501 Fifth Avenue
Pittsburgh, PA 15261

Ph: 412-624-7743

My Website »


  • Postdoc, Albert Einstein College of Medicine, 1990-1993
  • Postdoc, Scripps Clinic, 1987-1990
  • PhD, University of California at Berkeley, 1987
  • BS, University of California at Davis, 1982

Academic Affiliation

Professor, Department of Microbiology & Molecular Genetics

Professor, Department of Medicine, Division of Infectious Disease

Professor, Department of Immunology

Member, Graduate Program in Microbiology and Immunology (PMI)

About Research

Tuberculosis kills ~2 million people per year, worldwide. We use various animal models to study T cell, macrophage, dendritic cell, cytokine and chemokine responses to Mycobacterium tuberculosis in the lungs. Our goal is to define immune mechanisms that enhance resistance to this infection, as well as those that exacerbate pathology.  We study the early, chronic  and latent phase of infection, since it is estimated that 1/3 of the world's population is latently infected, and 10% of infected persons will develop active disease. These studies may lead to improved vaccine development or immunotherapeutic strategies, as well as a clear understanding of the host-pathogen interactions in tuberculosis. Our research encompasses translational studies on drugs, vaccines, and immune modulation of TB

Selected Publications

Lin PL, Ford CB, Coleman MT, Myers AJ, Gawande R, Ioerger T, Sacchettini J, Fortune SM, Flynn JL Sterilization of granulomas is common in both active and latent tuberculosis despite extensive within-host variability in bacterial killing. Nat Med. 2014 Jan;20(1):75-9. doi: 10.1038/nm.3412. Epub 2013 Dec 15. PMID:24336248.

Lin PL, Coleman T, Carney JP, Lopresti BJ, Tomko J, Fillmore D, Dartois V, Scanga C, Frye LJ, Janssen C, Klein E, Barry CE 3rd, Flynn JL. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother. 2013 Jun 24. [Epub ahead of print]. Sep 2013; 57(9): 4237–4244.  PMID:23796926. PMCID: PMC3754323

 Gong, C., Mattila, J.T., Miller, M., Flynn, J.L., Linderman, J.J., Kirschner, D. E. Predicting lymph node output efficiency through systems biology. 2013. J. Theor. Biol. 335C:169-184. PMID:23816876

Lin, P.L., Dartois, V., Johnston, P. J., Janssen, C., Via, L., Goodwin, M. B., Klein, E., Barry, C. E., III, Flynn, J. L. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc. Natl. Acad. Sci. 2012, 9(35):14188-93. July 23 [Epub ahead of print.] PMID: 22826237 PMCID:PMC3435210

Green, A., DiFazio, R. M., Flynn, J. L. 2012. IFN-γ from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection. J. Immunol. Dec 10 Epub ahead of print. Jan 1;190(1):270-7 PMID:23233724

Ragheb MN, Ford CB, Chase MR, Lin PL, Flynn JL, Fortune SM. The mutation rate of mycobacterial repetitive unit loci in strains of M. tuberculosis from cynomolgus macaque infection. BMC Genomics. 2013 Mar 5;14(1):145. [Epub ahead of print] PMID:23496945

Myers AJ, Marino S, Kirschner DE, Flynn JL. Inoculation dose of Mycobacterium tuberculosis does not influence priming of T cell responses in lymph nodes. J Immunol. 2013 May 1;190(9):4707-16. doi: 10.4049/jimmunol.1203465. Epub 2013 Apr 1. PMID:23547119

Diedrich CR, Mattila JT, Flynn JL. Monocyte-Derived IL-5 Reduces TNF Production by Mycobacterium tuberculosis-specific CD4 T Cells during SIV/M. tuberculosis Coinfection. J Immunol. 2013 Jun 15;190(12):6320-8. doi: 10.4049/jimmunol.1202043. Epub 2013 May 20. PMID:23690470

Mattila JT, Ojo OO, Kepka-Lenhart D, Marino S, Kim JH, Eum SY, Via LE, Barry CE 3rd, Klein E, Kirschner DE, Morris SM Jr, Lin PL, Flynn JL. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol. 2013. 191(2):773-84  Jun 7. [Epub ahead of print] PMID:23749634